HEALTH
THE LEDE
Multiple myeloma has a nasty habit: no matter how good the drug, it eventually finds a way around it. For thousands of patients living with this incurable blood cancer, that means an exhausting cycle of remission, relapse, and a scramble for the next line of defense. On August 13, 2026, the U.S. Food and Drug Administration handed doctors a genuinely new weapon in that fight — not a tweak of an old drug, but the first-ever approval in an entirely new class of cancer medicine. Zenbexus (iberdomide), developed by Bristol Myers Squibb, won accelerated approval in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma who have relapsed after at least one prior treatment. It's being hailed by oncologists as a milestone: the debut of "CELMoDs," a next-generation family of drugs engineered to be smarter, faster, and more precise than the myeloma medications that have anchored treatment for the past two decades.
WHAT MAKES THIS DRUG DIFFERENT
To understand why doctors are excited, it helps to understand the drugs Zenbexus is trying to replace. For years, the backbone of multiple myeloma treatment has included a class of drugs called immunomodulatory agents, or IMiDs — most famously Revlimid (lenalidomide) and Pomalyst (pomalidomide), both originally developed by Celgene before Bristol Myers Squibb acquired the company in 2019. These drugs work by binding to a protein called cereblon, which acts like a piece of cellular machinery that tags other proteins for destruction. IMiDs hijack that machinery to mark certain proteins inside myeloma cells for the cell's internal trash system, disrupting the cancer's survival signals.
Iberdomide, the active ingredient in Zenbexus, belongs to a newer, more refined category called cereblon E3 ligase modulators, or CELMoDs. Bristol Myers Squibb designed it to bind cereblon more tightly and degrade its target proteins faster and more completely than Revlimid or Pomalyst ever could — engineering, in essence, a more efficient wrecking crew. The goal is to overcome the drug resistance that eventually blunts the older IMiDs, giving oncologists a tool that keeps working even after a patient's cancer has learned to shrug off earlier treatments.
"This approval reflects the kind of innovation multiple myeloma patients have been waiting for," is the sentiment echoed across oncology circles since the approval, with specialists noting that CELMoDs represent the most significant structural evolution in this drug class since IMiDs themselves were introduced.
INSIDE THE TRIAL THAT WON THE APPROVAL
The FDA's decision rests on data from EXCALIBER-RRMM, a large Phase 3 trial that enrolled 939 patients with relapsed or refractory multiple myeloma who had received one or two prior lines of therapy. Patients were randomly assigned to receive either the new Zenbexus combination — iberdomide plus daratumumab, hyaluronidase-fihj, and dexamethasone, a regimen researchers call ZDd — or a standard comparator regimen combining daratumumab, bortezomib (Velcade), and dexamethasone, known as DVd.
At a median follow-up of 16 months, the results favored the new combination decisively on the trial's key measure: 41 percent of patients on the Zenbexus regimen achieved what's called an MRD-negative complete response, compared to just 21 percent of patients on the standard comparator. MRD stands for "measurable residual disease" — a state in which extremely sensitive lab tests can no longer detect any trace of cancer cells in a patient's bone marrow, even at levels far below what older methods could ever catch. Achieving MRD-negative status has increasingly become one of the most closely watched benchmarks in myeloma research, because it's associated with longer periods of remission and, researchers hope, better long-term survival, even though the FDA's use of MRD as a basis for accelerated approval here is itself a notable regulatory milestone — the agency is betting that clearing residual disease this thoroughly will translate into the traditional overwhelming evidence of benefit, like extended survival, that will need to be confirmed as the trial matures.
Because the approval is "accelerated" rather than a full, standard approval, Bristol Myers Squibb will be required to continue following patients and report back on more traditional outcomes — how long patients stay in remission, and ultimately how long they live — to convert this into a full approval down the road.
THE SAFETY TRADE-OFFS
No cancer drug arrives without a list of risks, and Zenbexus's label carries some serious ones. The most common side effects reported in at least one-fifth of patients on the Zenbexus combination included upper respiratory tract infections (54 percent), fatigue (36 percent), musculoskeletal pain (35 percent), pneumonia (34 percent), diarrhea (33 percent), motor dysfunction (26 percent), rash (26 percent), sleep disturbances (25 percent), low antibody levels known as hypogammaglobulinemia (24 percent), COVID-19 (23 percent), and constipation (20 percent).
More seriously, the drug carries boxed warnings — the FDA's strongest safety alert — for embryo-fetal toxicity, meaning it can cause severe birth defects and must not be used during pregnancy, and for venous and arterial thromboembolism, meaning dangerous blood clots in veins and arteries. Doctors are required to put patients on blood-thinning prophylaxis while taking the drug; even with those precautions in place, the trial recorded venous clotting events in 6.4 percent of patients and arterial events in 3.4 percent. Fatal adverse reactions occurred in 10 patients, or 4.9 percent of those who received Zenbexus during the trial — a sobering reminder that even breakthrough cancer therapies carry real risk, and that the decision to start one requires a careful conversation between patient and oncologist about the trade-offs involved.
THE PRICE TAG
Zenbexus will cost $29,500 for a single 28-day treatment cycle, according to Bristol Myers Squibb's pricing disclosures — a figure that places it firmly in line with, or above, many modern targeted cancer therapies, and one that will reignite ongoing debates about the affordability of cancer care in the United States. Wall Street analysts are already projecting big things for the drug commercially: sales forecasts have the medication crossing the $1 billion annual sales mark by 2031, positioning it as a potential blockbuster for Bristol Myers Squibb at a moment when the company badly needs one.
That need is not abstract. Revlimid, once one of the best-selling cancer drugs in the world with nearly $3 billion in 2025 sales, has been gutted by generic competition — its revenue crashed 49 percent year-over-year to just $425 million in the most recent quarter. Pomalyst has fared even worse, plunging 71 percent to $204 million in the same period. For a company that built much of its oncology franchise on those two drugs following its 2019 acquisition of Celgene, Zenbexus isn't just a scientific milestone — it's a financial lifeline, the next-generation product meant to carry the myeloma franchise into the 2030s as its predecessors fade into the generic-drug graveyard.
Notably, Zenbexus won't be alone for long. Bristol Myers Squibb has a second CELMoD, mezigdomide, working its way through late-stage trials; in a separate Phase 3 study called SUCCESSOR-2, mezigdomide combined with carfilzomib and dexamethasone produced a median progression-free survival of 18 months, more than double the 8.3 months seen with a standard comparator regimen — early signs that this new drug class could reshape myeloma treatment across multiple points in a patient's disease journey, not just after first relapse.
WHY THIS MATTERS BEYOND MYELOMA PATIENTS
Multiple myeloma is the second most common blood cancer in the United States, with roughly 35,000 new cases diagnosed annually, according to figures widely cited by patient advocacy groups like the International Myeloma Foundation and the Multiple Myeloma Research Foundation. It remains, for the vast majority of patients, an incurable disease — one defined by cycles of treatment, remission, and eventual relapse, as cancer cells slowly develop resistance to whatever combination of drugs is thrown at them. That grinding, repetitive reality is exactly why oncologists have been so eager for a genuinely new mechanism of action, rather than another reshuffling of existing drug combinations.
"What you should know about the new Zenbexus approval" has become a common refrain across patient advocacy communications in the days since the FDA's decision, reflecting real hunger among patients and caregivers for plain-language explanations of what a "first-in-class" approval actually changes for someone sitting in an infusion chair. The honest answer, according to specialists, is that it's a meaningful new option — not a cure, and not right for every patient, but a genuine expansion of the treatment toolkit at a stage of disease, first relapse, where oncologists have historically had fewer great options than patients might assume.
WHAT THIS MEANS FOR YOU
If you or a loved one is living with multiple myeloma, Zenbexus is now a treatment option worth discussing with your oncologist specifically at the point of first relapse — the moment your original treatment stops working as well as it once did. It is not currently approved as a first-line treatment for newly diagnosed patients, and it comes with serious risks that require careful monitoring, including mandatory blood clot prevention measures and close attention to infection risk given how commonly infections showed up in the trial data. Cost will also be a major factor in real-world access; patients should ask their care team and insurance provider early about coverage, copay assistance programs, and manufacturer support, given the $29,500-per-cycle price tag.
For the broader public without a personal connection to myeloma, this approval is worth understanding as a bellwether. CELMoDs represent a genuine engineering advance in cancer drug design — proof that decades-old drug classes can still be meaningfully reinvented rather than simply replaced by entirely different approaches like CAR-T cell therapy or bispecific antibodies, which have also transformed myeloma care in recent years. Expect to hear the term "CELMoD" again soon, as Bristol Myers Squibb and likely competitors push more drugs in this class through the pipeline.
CONCLUSION
For a disease that has spent decades teaching doctors the same painful lesson — that today's best drug is tomorrow's resistant tumor — the arrival of an entirely new mechanism carries outsized significance. Zenbexus won't be the last word in multiple myeloma treatment, and its full survival data is still years away from maturing. But its approval marks the start of a new chapter in the CELMoD story, one that Bristol Myers Squibb, its patients, and its Wall Street investors will all be watching closely as this next generation of cancer drugs works its way from Phase 3 trials into infusion centers across the country.
